Search for: "Boehringer Ingelheim Pharmaceuticals"
Results 161 - 180
of 252
Sorted by Relevance
|
Sort by Date
9 Mar 2015, 2:38 pm
Litigation and Government Investigations at Boehringer Ingelheim Pharmaceuticals where she oversaw all U.S. litigation and government investigations. [read post]
6 May 2024, 8:26 am
” Warning letters were sent to 10 manufacturers, including, among others, Teva (identifying 58 listings), Novo Nordisk (36 listings), and Boehringer Ingelheim (10 listings). [read post]
9 Mar 2012, 10:54 am
Pradaxa (dabigatran etexilate), manufactured by Boehringer Ingelheim Pharmaceuticals, was supposed to be one of those replacements. [read post]
9 Jul 2015, 3:28 pm
Boehringer Ingelheim ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. [read post]
29 Mar 2024, 5:21 am
Case BackgroundEmpagliflozin (branded as Jardiance) is marketed in the EU by Eli Lilly and Boehringer Ingelheim for the treatment of type II diabetes (EU/1/14/930). [read post]
3 Mar 2012, 6:48 am
(But not the two new huge drug cases: Boehringer Ingelheim, maker of Pradaxa, is in Connecticut, while Takeda, maker of Actos, is in Illinois.) [read post]
18 Oct 2012, 6:18 am
Things To Know About Pradaxa Blood Thinner Drug Side Effect and Lawsuits Pradaxa, generic name Dabigatran, is an oral anticoagulant drug manufactured by German pharmaceutical Boehringer Ingelheim. [read post]
18 Sep 2013, 2:05 pm
In the U.S. market, Xarelto competes with Eliquis, sold by Pfizer and Bristol-Myers Squibb, and with Boehringer Ingelheim's Pradaxa.The next day's Reuters news report presented the German drug regulator reaction to this Xarelto Der Spiegel magazine article about Xarelto: The number of reported side effects linked to Bayer's stroke prevention pill Xarelto is below worrisome levels, a German drugs regulator said, responding to a media report highlighting risks from taking the blood… [read post]
26 Apr 2007, 9:28 am
The two big trade mark decisions of the European Court of Justice today have been a little overshadowed by the festivities for World Intellectual Property Day, but the IPKat took just enough time off from his ecstatic celebrations to check the Curia website and see what the ECJ had in store for him.Right: objection to the repackaging of pharma products has led to some grey goods traders taking extreme measures to avoid trade mark infringment litigationCase C-348/04, Boehringer… [read post]
19 Oct 2012, 7:36 am
The British regulatory agency, the Prescription Medicines Code of Practice Authority, PMCPA, accused Boehringer Ingelheim of violating the pharmaceutical code of conduct in December 2011. [read post]
2 Aug 2012, 10:31 am
Pradaxa is manufactured by German pharmaceutical company Boehringer Ingelheim and marketed as an alternative to Coumadin (warfarin), a widely used oral anticoagulant. [read post]
18 Mar 2010, 2:30 am
Mylan Pharmaceuticals, Inc. et al. [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
1 Aug 2013, 9:29 am
• Liraglutide (Victoza) marketed by Novo Nordisk • Sitagliptin (Januvia, Janumet & Juvisync) marketed by Merck • Saxagliptin (Onglyza & Kombiglyze) marketed by Bristol-Myers Squibb in partnership with Astrazeneca • Alogliptin (Nesina, Kazano & Oseni) marketed by Takeda Pharmaceuticals • Linagliptin (Tradjenta & Jentadueto) marketed by Eli Lilly and Boehringer Ingelheim While the drug industry continues to ignore or deny the… [read post]
11 Jan 2024, 12:03 am
The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer. [read post]
26 Aug 2009, 6:12 am
F. of L. files antitrust suit against Merck, alleging fraudulent procurement of a patent, improper listing of patent in Orange Book (Patent Docs) Singulair (Montelukast) – US: Merck get injunction preventing Teva from selling generic Montelukast: Merck Sharp & Dohme Pharmaceuticals SRL v Teva Pharmaceuticals USA (The IP Factor) (IP Watchdog) (SmartBrief) (SmartBrief) (GenericsWeb) [read post]
14 Jul 2010, 6:47 pm
Boehringer Ingelheim Pharma (EPLAW) Plavix (Clopidogrel) – US: Apotex’s second request for re-examination of Plavix patent denied by USPTO (Patent Docs) Tarka (Trandolapril, Verapamil) – Sanofi, Abbott successfully request sanctions against Glenmark in Tarka dispute (Patent Docs) [read post]
15 Jun 2012, 2:51 pm
Pradaxa Approved by FDA in 2010 and Investigated by 2011 In 2010, the United States Food & Drug Administration (FDA) approved Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., as a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
15 Jun 2012, 2:51 pm
Pradaxa Approved by FDA in 2010 and Investigated by 2011 In 2010, the United States Food & Drug Administration (FDA) approved Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., as a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. [read post]
